Chlamydia – caused by infection with Chlamydia trachomatis (CT) bacterium – is the most frequently reported bacterial sexually transmitted infection in the United States.1-3 

It spreads through vaginal, anal, or oral sex with an infected person.3

CT is most common among young people.1-3 


1 in 20 sexually active young
women aged 14-24 has CT.3

2 out of 3 new CT infections occur
among youth aged 15-24 years.1


CT causes a silent infection, which means that most people have no symptoms, no abnormal physical findings and do not seek care.3 


Only 6%of women with a confirmed CT infection develop symptoms.4


25% Increase in CT rates between 2013 and 2018 despite control efforts.5*


If untreated, CT infections increase the risk of serious health problems for women.3

Pelvic inflammatory disease (PID)

Chlamydia can spread to the uterus or fallopian tubes, causing PID.  Long-term damage can include chronic pelvic pain, tubal factor infertility, and potentially fatal ectopic pregnancy.3

Problems in pregnancy

Untreated chlamydia can lead to preterm delivery, ophthalmia neonatorum (conjunctivitis), and pneumonia in newborns.3


Fitz-Hugh-Curtis (FHC) Syndrome

Some patients with PID develop perihepatitis, or FHC, leading to inflammation of the liver capsule and surrounding peritoneum.3

Reiter’s Syndrome

A combination of urethritis, conjunctivitis, and reactive arthritis resulting from untreated CT.3


Screening is necessary to identify most CT infections

Screening for CT is critical for healthcare providers to detect infection, since CT usually has no symptoms.2



Yearly chlamydia screening is recommended for all sexually active women under age 25 and older women at risk of infection.2



Chlamydia screening programs can dramatically improve health outcomes and have been shown to reduce pelvic inflammatory disease rates among women.2,6

There are 3 common screening methods for CT


A swab of the discharge from the cervix is taken for culture or antigen testing for chlamydia and may be done during a routine Pap test.


Some women prefer to swab their vagina themselves in the healthcare setting. Patient-collection of vulvovaginal swabs has excellent sensitivity in women with and without symptoms, when associated with nucleic acid amplification testing (NAAT), like the BD CTGCTV2 assay.7

Urine test

A urine sample is analyzed in the laboratory.

The BD CTGCTV2 assay is cleared for all 3 screening methods and is designed to detect CT, GC, and TV—the 3 most prevalent non-viral sexually transmitted infections—in a single test.5,8,9

Learn More

*In 2020, CT rates decreased by 13% compared to 2019, likely due to decreases in STD screening and underdiagnosis during the COVID-19 pandemic.1

CT, Chlamydia trachomatis; FDA, Food and Drug Administration; FHC, Fitz-Hugh-Curtis; GC, Neisseria gonorrhoeae; NAAT, nucleic acid amplification test;
PID, pelvic inflammatory disease; STI, sexually transmitted infection; TV, Trichomonas vaginalis.

1. National Overview - Sexually Transmitted Disease Surveillance 2020, CDC. 2022. Accessed 29 Apr 2022. 
2. Workowski KA et al. MMWR Recomm Rep. 2021;70(4):1–187.
3. Chlamydia – CDC Fact Sheet, CDC. 2022. Accessed 10 Apr 2022. 
4. Korenromp EL et al. Int J STD AIDS. 2002;13(2):91–101.
5. Van Der Pol B et al. Sex Transm Dis. 2021;48(2):134–40.
6. Scholes D et al. Sex Transm Dis. 2012;39(2):81–8. 
7. Page C et al. J Fam Pract. 2013;62(11):651–3.
8. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, CDC. 2021. Accessed 29 Apr 2022.
9. BD CTGCTV2 for BD MAX™ System Package Insert [P0237].